JP2007520488A5 - - Google Patents

Download PDF

Info

Publication number
JP2007520488A5
JP2007520488A5 JP2006550998A JP2006550998A JP2007520488A5 JP 2007520488 A5 JP2007520488 A5 JP 2007520488A5 JP 2006550998 A JP2006550998 A JP 2006550998A JP 2006550998 A JP2006550998 A JP 2006550998A JP 2007520488 A5 JP2007520488 A5 JP 2007520488A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
quetiapine
bipolar disorder
bipolar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006550998A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007520488A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2005/000094 external-priority patent/WO2005072742A1/en
Publication of JP2007520488A publication Critical patent/JP2007520488A/ja
Publication of JP2007520488A5 publication Critical patent/JP2007520488A5/ja
Pending legal-status Critical Current

Links

JP2006550998A 2004-01-30 2005-01-27 クエチアピン抗精神病薬による精神病の治療 Pending JP2007520488A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54061804P 2004-01-30 2004-01-30
PCT/SE2005/000094 WO2005072742A1 (en) 2004-01-30 2005-01-27 Treatment of psychoses with quetiapine antipsychotic

Publications (2)

Publication Number Publication Date
JP2007520488A JP2007520488A (ja) 2007-07-26
JP2007520488A5 true JP2007520488A5 (https=) 2008-03-21

Family

ID=34826230

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006550998A Pending JP2007520488A (ja) 2004-01-30 2005-01-27 クエチアピン抗精神病薬による精神病の治療

Country Status (13)

Country Link
US (2) US20050171088A1 (https=)
EP (1) EP1713488A1 (https=)
JP (1) JP2007520488A (https=)
KR (1) KR20070011276A (https=)
CN (1) CN1913902A (https=)
AU (1) AU2005209142A1 (https=)
BR (1) BRPI0507086A (https=)
CA (1) CA2495361A1 (https=)
IL (1) IL176999A0 (https=)
NO (1) NO20063856L (https=)
RU (1) RU2006130687A (https=)
WO (1) WO2005072742A1 (https=)
ZA (1) ZA200606128B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
WO2006073360A1 (en) * 2005-01-07 2006-07-13 Astrazeneca Ab NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f] [1,4] THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS
US8389510B2 (en) 2005-11-18 2013-03-05 Astrazeneca Ab Crystalline forms
TW200735878A (en) * 2005-11-18 2007-10-01 Astrazeneca Ab Pharmaceutical compositions
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
US8017785B2 (en) 2006-05-09 2011-09-13 Astrazeneca Ab Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
US8682445B2 (en) * 2006-07-28 2014-03-25 Cyberonics, Inc. Patient management system for treating depression using an implantable medical device
EP2120957A4 (en) * 2006-12-20 2011-05-04 Astrazeneca Ab COMPOUNDS AND USES THEREOF
CN107714703A (zh) 2009-12-31 2018-02-23 凯姆制药公司 喹硫平的氨基酸缀合物、其制备和使用方法
EP3476218A1 (en) 2010-03-11 2019-05-01 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
US8703802B2 (en) 2010-05-20 2014-04-22 Targacept, Inc. Process for the preparation of aryl substituted olefinic amines
CN102631350B (zh) * 2012-03-29 2013-10-16 南京正科制药有限公司 一种富马酸喹硫平与鲁拉西酮的复方制剂
CN102716133A (zh) * 2012-04-06 2012-10-10 中国人民解放军第三军医大学 喹硫平在制备预防和治疗自身免疫性疾病的药物中的应用
CN109464451B (zh) * 2019-01-15 2021-07-13 范崇桂 一种治疗神经衰弱的药物及其制备方法
RU2717939C1 (ru) * 2019-10-29 2020-03-27 Государственное бюджетное учреждение Санкт-Петербургский научно-исследовательский институт скорой помощи им. И.И. Джанелидзе Способ лечения интоксикационных психозов при острых отравлениях психоактивными веществами

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US6622036B1 (en) * 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
DE1073432T1 (de) * 1998-04-14 2002-02-07 The General Hospital Corp., Boston Verwendung von glycinrezeptoragonisten und glycinaufnahmeinhibitoren zur behandlung neuropsychiatrischer beschwerden
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
US20030027817A1 (en) * 1998-05-29 2003-02-06 Tollefson Gary Dennis Combination therapy for treatment of bipolar disorders
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6194466B1 (en) * 1998-10-15 2001-02-27 Elizabeth Marie Cottingham Use of metformin to counteract weight gain associated with valproate and other psychotropic medications
US20030096808A1 (en) * 1999-03-29 2003-05-22 Jon M. Miller Substance to prevent or reverse weight gain induced by psychoactive agents
US6489341B1 (en) * 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
US6350773B1 (en) * 1999-12-10 2002-02-26 American Home Products Corporation Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
US6599532B2 (en) * 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent
US6572890B2 (en) * 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
US20020061339A1 (en) * 2000-09-28 2002-05-23 Martin Stogniew Compositions and methods for use of extracts of rutaceae plants
US20050054942A1 (en) * 2002-01-22 2005-03-10 Melker Richard J. System and method for therapeutic drug monitoring
JP2004517112A (ja) * 2001-01-02 2004-06-10 ファルマシア・アンド・アップジョン・カンパニー 新規薬物コンビネーション
US7053092B2 (en) * 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
ATE360425T1 (de) * 2001-02-06 2007-05-15 Astrazeneca Ab Verwendung von quetiapin für die behandlung von kokain-abhängigkeit
US20020123490A1 (en) * 2001-03-01 2002-09-05 Pfizer Inc. Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
CA2445528A1 (en) * 2001-04-26 2002-11-07 Ortho-Mcneil Pharmaceutical, Inc. Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
US6621096B2 (en) * 2001-05-21 2003-09-16 Hewlett-Packard Develpoment Company, L.P. Device isolation process flow for ARS system
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
EA009780B1 (ru) * 2001-06-19 2008-04-28 Норберт Мюллер Применение ингибиторов cox-2 для лечения шизофрении, аффективных расстройств или осложнений, связанных с тиком
DE10129320A1 (de) * 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
CA2454339C (en) * 2001-07-23 2012-01-10 Corcept Therapeutics, Inc. Methods for preventing antipsychotic-induced weight gain
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
GB0202900D0 (en) * 2002-02-07 2002-03-27 Laxdale Ltd Novel formulations of drugs
US6831077B2 (en) * 2002-07-25 2004-12-14 Comprehensive Neuroscience, Inc. Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation
AU2003259256A1 (en) * 2002-07-29 2004-02-16 Potomac Pharma, LLC. Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic
AU2003268026A1 (en) * 2002-07-30 2004-02-16 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
CN1741803A (zh) * 2003-01-23 2006-03-01 阿卡蒂亚药品公司 N－脱甲基氯氮平在治疗人神经精神疾病中的用途
WO2004100992A2 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
US20050171139A1 (en) * 2003-10-07 2005-08-04 Hammer Ronald P.Jr. Treating psychotic symptoms
US20050158383A1 (en) * 2003-10-21 2005-07-21 Garth Boehm Quetiapine formulations
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
SG133606A1 (en) * 2003-12-22 2007-07-30 Acadia Pharm Inc Amino substituted diaryl [a,d] cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
WO2005063296A2 (en) * 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders
JP2007519705A (ja) * 2004-01-29 2007-07-19 ファイザー・プロダクツ・インク Ｃｎｓ障害を治療するための非定型抗精神病薬とアミノメチルピリジルオキシメチル／ベンゾイソオキサゾールアザビシクロ誘導体の組合せ
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
WO2005079807A1 (en) * 2004-02-13 2005-09-01 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
US20050181071A1 (en) * 2004-02-18 2005-08-18 Binder Michael R. Method for the treatment of clinical depression
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
BRPI0510942A (pt) * 2004-05-11 2007-07-17 Pfizer Prod Inc combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b
US20050261278A1 (en) * 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US8285900B2 (en) * 2009-02-17 2012-10-09 The Board Of Regents Of The University Of Texas System Method and apparatus for congestion-aware routing in a computer interconnection network

Similar Documents

Publication Publication Date Title
JP2007520488A5 (https=)
JP2022191257A5 (https=)
US20080262053A1 (en) Use of Pramipexole for Treating Moderate to Severe Restless Legs Syndrome (Rls)
JP2018518537A5 (https=)
JP2005506370A5 (https=)
RS51961B (sr) Primena flibanserina za lečenje poremećaja seksualne želje u premenopauzi
JP2007533687A5 (https=)
RU2006140964A (ru) Применение флибансерина для лечения предменструальных и иных сексуальных расстройств у женщин
JP2010518029A5 (https=)
RU2006130687A (ru) Лечение психозов антипсихотическим агентом кветиапином
JP2009511568A5 (https=)
US20250032503A1 (en) Use of aprepitant for treating alzheimer's disease
BRPI0414347A (pt) associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade
CN107835695A (zh) 用于治疗自闭症的组合物和方法
EP4494701A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
US20020183306A1 (en) Combination treatment for sleep disorders including sleep apnea
JP2002544227A5 (https=)
TW200735878A (en) Pharmaceutical compositions
CN109310669B (zh) 氨基甲酸酯化合物用于预防或治疗三叉神经痛的用途
CN101316584A (zh) 用于预防及治疗由血管通透性亢进引起的眼病的医药
JP4354180B2 (ja) 軽度認知障害治療剤
Shinno et al. Successful treatment with levothyroxine for idiopathic hypersomnia patients with subclinical hypothyroidism
JP2008533079A5 (https=)
EP1247533A2 (en) Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
JP2007509946A5 (https=)